Numerous reports have documented drug interactions with grapefruit juice (GFJ) that occur via inhibition of CYP3A enzymes. As reported by Glaeser et al. in the March 2007 issue of this journal, there is increasing recognition that GFJ may also affect the activity of influx (e.g., OATPs) and efflux (e.g., P-glycoprotein) transporters. This commentary focuses on these interactions between GFJ and drug transporters.
